ArticleDermatology and therapy2026

Real-World Evidence of Upadacitinib in Atopic Dermatitis after Inadequate Response or Intolerance to Dupilumab: The CAN UpTIMISE Study.

Vimal H Prajapati et al.PubMed ↗Publisher ↗

No numbers read from the abstract.